No products in the cart.
-
Sale
Alarid 1 mgAlarid 1 mg is indicated in the prophylactic treatment of bronchial asthma, symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.Theropeutic ClassCromoglycate & related drugsPharmacologyAlarid 1 mg is a potent anti-allergic substance possessing a powerful and sustained non-competitive histamine (H1) receptor blocking property. It inhibits the release of mediators (e.g histamine, leukotrienes and prostaglandins) from cells responsible for type-(I) allergic reactions. Alarid 1 mg also stabilizes mast cells, decreases chemotaxis, activation of degranulation of eosinophils.??Also, it stabilizes mast cells & basophils and inhibits PAF (platelet activating factor) and is effective in preventing asthmatic attacks.Dosage & Administration of Alarid 1 mgAdults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases. Children above 2 years: 1 mg twice daily with food. Patient?s known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician. Use in elderly: Same as adult dose or as advised by the physician.Interaction of Alarid 1 mgA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetics and it has been suggested that this combination should therefore be avoided. Since Ketotifen has the properties of the antihistamines, it may potentiate the effects of other CNS depressant drugs such as alcohol, antihistamines, hypnotics and sedatives.ContraindicationsA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided.Side Effects of Alarid 1 mgDrowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment, but usually disappear spontaneously after a few days.Pregnancy & LactationAlthough there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.Precautions & WarningsAlarid 1 mg is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If intercurrent infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patient should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotic, antihistamines and alcohol.Overdose Effects of Alarid 1 mgSymptoms: Drowsiness, confusion, dyspnoea, bradycardia or tachycardia, disorientation, convulsions, severe hypotension, reversible coma.Management: Supportive and symptomatic.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Alarid1 mg
Original price was: ₦165.00.₦148.50Current price is: ₦148.50.
0.48792
0.00000
0.00004
0.00101
0.11155
-
SaleAlarid 100 mlAlarid 100 ml is indicated in the prophylactic treatment of bronchial asthma, symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.Theropeutic ClassCromoglycate & related drugsPharmacologyAlarid 100 ml is a potent anti-allergic substance possessing a powerful and sustained non-competitive histamine (H1) receptor blocking property. It inhibits the release of mediators (e.g histamine, leukotrienes and prostaglandins) from cells responsible for type-(I) allergic reactions. Alarid 100 ml also stabilizes mast cells, decreases chemotaxis, activation of degranulation of eosinophils.??Also, it stabilizes mast cells & basophils and inhibits PAF (platelet activating factor) and is effective in preventing asthmatic attacks.Dosage & Administration of Alarid 100 mlAdults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases. Children above 2 years: 1 mg twice daily with food. Patient?s known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician. Use in elderly: Same as adult dose or as advised by the physician.Interaction of Alarid 100 mlA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetics and it has been suggested that this combination should therefore be avoided. Since Ketotifen has the properties of the antihistamines, it may potentiate the effects of other CNS depressant drugs such as alcohol, antihistamines, hypnotics and sedatives.ContraindicationsA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided.Side Effects of Alarid 100 mlDrowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment, but usually disappear spontaneously after a few days.Pregnancy & LactationAlthough there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.Precautions & WarningsAlarid 100 ml is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If intercurrent infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patient should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotic, antihistamines and alcohol.Overdose Effects of Alarid 100 mlSymptoms: Drowsiness, confusion, dyspnoea, bradycardia or tachycardia, disorientation, convulsions, severe hypotension, reversible coma.Management: Supportive and symptomatic.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.
Alarid100 ml
Original price was: ₦4,125.00.₦3,712.50Current price is: ₦3,712.50.
12.19803
0.00003
0.00106
0.02514
2.78869
-
SaleAlbasine 30 mg+10 mgThis tablet is indicated for- Reduction of neurological damage & accelerates recovery after cerebral stroke Minor age-related neurological disorders Some visual disorders related to the circulation Some disorders of the inner ear related to circulation (hearing loss, dizziness, buzzing sounds in the ear). Theropeutic ClassCerebral vasodilator & Neurosensory oxygenator drugsPharmacologyAlmitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.Dosage & Administration of Albasine 30 mg+10 mgUsually 1-2 tablets daily (with a several hours interval).Dosage of Albasine 30 mg+10 mg1 tablet once or twice daily (taken separately, several hours apart), without exceeding 2 tablets per day. Or, as directed by the registered physicians.Interaction of Albasine 30 mg+10 mgDo not associate with MAO-l (monoamine oxidase inhibitor), Not to be used concurrently with other almitrine-containing preparations.ContraindicationsThis tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.Side Effects of Albasine 30 mg+10 mgWeight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations.Pregnancy & LactationConsulting with physicians is required to take this medicine.Precautions & WarningsDue to the presence of lactose, this drug should not be used in the case of galactosemia, of glucose and galactose malabsorption syndrome or of lactose deficiency (rare metabolic diseases). Do not exceed the recommended dose.Overdose Effects of Albasine 30 mg+10 mgSigns include tachycardia, arterial hypotension, polypnoea and respiratory alkalosis.Storage ConditionsStore at a cool and dry place, protected from light and moisture. Keep out of reach of children.Drug ClassesCerebral vasodilator & Neurosensory oxygenator drugsMode Of ActionAlmitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.PregnancyIt is not recommended in pregnancy. It should be used with caution only when the expected benefit to the mother is greater than the possible risk to the fetus.
Albasine30 mg+10 mg
Original price was: ₦9,240.00.₦8,316.00Current price is: ₦8,316.00.
27.32359
0.00008
0.00237
0.05632
6.24666
-
SaleAldocort 0.10 mgUsed for oral mineralocorticoid replacement therapy in: Primary and secondary adrenocortical insufficiency in Addison?s disease Salt losing adrenogenital syndrome Postural hypotension Theropeutic ClassCorticosteroidPharmacologyFludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises?extracellular fluid volume and blood pressure and lowers potassium levels.Dosage & Administration of Aldocort 0.10 mgPrimary and secondary Adrenocortical Insufficiency in Addison?s disease: Usual dose may range from 0.2 mg 3 times weekly to 0.2 mg daily. If hypertension occurs, reduce dosage to 0.05 mg daily. Administer concomitantly with Cortisone or hydrocortisone.Salt-Losing Adrenogenital Syndrome: 0.1 to 0.2 mg/day.Postural Hypotension: 0.1-0.4 mg daily to diabetic patients with postural hypotension; 0.05-0.2 mg daily to patients with postural hypotension secondary to Levodopa therapy.Dosage of Aldocort 0.10 mgPrimary and secondary Adrenocortical Insufficiency in Addison?s disease: Usual dose may range from 0.2 mg 3 times weekly to 0.2 mg daily. If hypertension occurs, reduce dosage to 0.05 mg daily. Administer concomitantly with Cortisone or hydrocortisone.Salt-Losing Adrenogenital Syndrome: 0.1 to 0.2 mg/day.Postural Hypotension: 0.1-0.4 mg daily to diabetic patients with postural hypotension; 0.05-0.2 mg daily to patients with postural hypotension secondary to Levodopa therapy.Interaction of Aldocort 0.10 mgInteractions can occur with following drugs: Amphotericin B, potassium depleting diuretics, anticholinesterases, anticoagulants, antidiabetics. Antitubercular drugs, cyclosporine, digitalis glycosides, oral contraceptives and ketoconazole .ContraindicationsIn case of adrenal insufficiency, no absolute contraindications are applicable. In the treatment of non-endocrine diseases where pharmacological dose are more likely to be used, the contraindications to be considered carefully. Relative contraindications include: systemic fungal infection, hypersensitivity to Fludrocortisone, diabetic mellitus, osteoporosis and acute infection.Side Effects of Aldocort 0.10 mgMost adverse reactions are caused by the drug?s mineralocorticoid activity (retention of sodium andwater) include erythema, purpura, vertigo, pancreatitis, increased intraocular pressure, muscular weakness, hypertension, edema, cardiac enlargement, congestive heart failure, steroid myopathy, peptic ulcer, osteoporosis, convulsions, menstrual irregularities, potassium loss, hypokalemic alkalosis, allergic and anaphylactic reaction etc. When Fludrocortisones is used in the small dosages recommended, side effects are not usually a problem; however the above mentioned unwanted effects should be kept in mind, particularly when Fludrocortisones is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid.Pregnancy & LactationPregnancy category C. There are no adequate and well-controlled studies in pregnant women. Fludrocortisone is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.Lactation: There are no data on the excretion of fludrocortisone into human milk. However, corticosteroids (systemic therapy) are distributed into breast milk and could cause growth suppression and/or other adverse effects in nursing infants. The manufacturer recommends that caution be used when administering Fludrocortisone to nursing women.Precautions & WarningsBecause of its marked effect on sodium retention, the use of Fludrocortisone in the treatment of conditions other than those indicated herein is not advised. Fludrocortisone should be used with caution in patients suffering from different infections (like tuberculosis, measles, chicken pox, herpes zoster or threadworm infestation), congestive cardiac failure, hypertension, renal insufficiency, osteoporosis, drug-induced secondary adrenocortical insufficiency, peptic ulcer, intestinal anastomosis and ulcerative colitis.Overdose Effects of Aldocort 0.10 mgOverdose is unlikely; however, treatment of overdose is by supportive and symptomatic therapy.Storage ConditionsStore in a cool and dry place, protected from light.Drug ClassesCorticosteroidMode Of ActionFludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises?extracellular fluid volume and blood pressure and lowers potassium levels.PregnancyPregnancy category C. There are no adequate and well-controlled studies in pregnant women. Fludrocortisone is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.Lactation: There are no data on the excretion of fludrocortisone into human milk. However, corticosteroids (systemic therapy) are distributed into breast milk and could cause growth suppression and/or other adverse effects in nursing infants. The manufacturer recommends that caution be used when administering Fludrocortisone to nursing women.
Aldocort0.10 mg
Original price was: ₦550.00.₦495.00Current price is: ₦495.00.
1.62640
0.00000
0.00014
0.00335
0.37182
-
SaleAldonist 25 mgCongestive heart failure after an acute myocardial infarction, Hypertension.Theropeutic ClassPotassium-sparing diuretics, Potassium-sparing diuretics & Aldosterone antagonistsPharmacologyAldonist 25 mg selectively binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a key component in the renin-angiotensin-aldosterone-system, which is involved in the regulation of BP and pathophysiology of CV disease. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g. kidney, GI tract) and nonepithelial (e.g. heart, blood vessels, brain) tissues; causing increases in BP by inducing Na reabsorption, vascular remodelling, water retention, endothelial dysfunction and possibly other mechanisms.Dosage & Administration of Aldonist 25 mgCongestive Heart Failure after an acute Myocardial Infarction:?The recommended dose of Aldonist 25 mg is 50 mg once daily. Treatment should be initiated at 25 mg once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks as tolerated by the patient. Aldonist 25 mg may be administered with or without food.Hypertension: Aldonist 25 mg may be used alone or in combination with other antihypertensive agents. The recommended starting dose of Aldonist 25 mg is 50 mg administered once daily. For patients with an inadequate blood pressure response to 50 mg once daily the dosage of Aldonist 25 mg should be increased to 50 mg twice daily. Higher dosages of Aldonist 25 mg are not recommended either because they have no greater effect on blood pressure than 100 mg or because they are associated with an increased risk of hyperkalemia.Dosage of Aldonist 25 mgCongestive Heart Failure after an acute Myocardial Infarction:?The recommended dose of Aldonist 25 mg is 50 mg once daily. Treatment should be initiated at 25 mg once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks as tolerated by the patient. Aldonist 25 mg may be administered with or without food.Hypertension: Aldonist 25 mg may be used alone or in combination with other antihypertensive agents. The recommended starting dose of Aldonist 25 mg is 50 mg administered once daily. For patients with an inadequate blood pressure response to 50 mg once daily the dosage of Aldonist 25 mg should be increased to 50 mg twice daily. Higher dosages of Aldonist 25 mg are not recommended either because they have no greater effect on blood pressure than 100 mg or because they are associated with an increased risk of hyperkalemia.Interaction of Aldonist 25 mgMay increase risk of hyperkalaemia with ACE inhibitors and/or angiotension receptor blocker, ciclosporin, tacrolimus, trimethoprim. May reduce antihypertensive effect with NSAIDs, glucocorticoids, tetracosactide. May enhance hypotensive effect of ?1-blockers (e.g. alfuzosin, prazosin), TCAs, amifostine, baclofen, neuroleptics. May increase plasma level with mild to moderate CYP3A4 inhibitors (e.g. fluconazole, erythromycin, saquinavir, amiodarone, diltiazem, verapamil).ContraindicationsAldonist 25 mg is contraindicated in- Hyperkalaemia Severe renal impairment (creatinine clearance less than 30 ml/min) Severe hepatic impairment Concomitant use with potent CYP3A4 inhibitors like Ketoconazole, Itraconazole, Nefazodone, Troleandomycin, Clarithromycin, Ritonavir, and Nelfinavir or other Potassium-sparing diuretics are also contraindicated Side Effects of Aldonist 25 mgHeadache, dizziness, diarrhea, stomach pain, nausea, cough or flu-like symptoms may occur. Symptoms of a serious allergic reaction like: rash, itching, swelling, severe dizziness, trouble breathing can occur.Pregnancy & LactationPregnancy: There are no adequate and well-controlled studies in pregnant women. Aldonist 25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: The concentration of Aldonist 25 mg in human breast milk after oral administration is unknown. Because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & WarningsAldonist 25 mg should be used with caution in hyperkalemia, severe kidney disease, diabetic patients with congestive heart failure after an acute myocardial infarction including those with proteinuria.Overdose Effects of Aldonist 25 mgSymptoms: Hyperkalaemia, hypotension. Management: Symptomatic and supportive treatment. Admin activated charcoal. Initiate standard therapy for hyperkalaemia.Storage ConditionsStore below 30?C in a cool and dry place, protected from light and moisture. Keep out of children?s reach.Use In Special PopulationsPediatric use: The safety and effectiveness of Aldonist 25 mg has not been established in pediatric patients.Geriatric use: No differences in overall incidence of effectivity or safety was observed in elderly patients.Drug ClassesPotassium-sparing diuretics, Potassium-sparing diuretics & Aldosterone antagonistsMode Of ActionAldonist 25 mg selectively binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a key component in the renin-angiotensin-aldosterone-system, which is involved in the regulation of BP and pathophysiology of CV disease. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g. kidney, GI tract) and nonepithelial (e.g. heart, blood vessels, brain) tissues; causing increases in BP by inducing Na reabsorption, vascular remodelling, water retention, endothelial dysfunction and possibly other mechanisms.PregnancyPregnancy: There are no adequate and well-controlled studies in pregnant women. Aldonist 25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: The concentration of Aldonist 25 mg in human breast milk after oral administration is unknown. Because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UsesPediatric use: The safety and effectiveness of Aldonist 25 mg has not been established in pediatric patients.Geriatric use: No differences in overall incidence of effectivity or safety was observed in elderly patients.
Aldonist25 mg
Original price was: ₦17,325.00.₦15,592.50Current price is: ₦15,592.50.
51.23172
0.00014
0.00444
0.10561
11.71248
-
SaleAldorin 50 mgAldorin 50 mg consequently improves peripheral neuropathy due to sorbitol accumulation. It is usually used to improve numbness, pain and abnormality of vibration sensation/heart rate variability associated with diabetic peripheral neuropathy.Theropeutic ClassAldose reductase inhibitorPharmacologyAldorin 50 mg is aldose reductase inhibitor. The aldose reductase inhibitors have a distinct mechanism of action, affecting the underlying disease process in diabetic neuropathy, although the extent of the polyol pathway involvement is yet to be determined. This medicine suppresses accumulation of sorbitol in cells by inhibiting action of aldose reductase which converts glucose of sugar to sorbitol. Aldorin 50 mg may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms.Dosage & Administration of Aldorin 50 mgIn general, for adults, take 1 tablet (50 mg of the active ingredient) at a time, 3 times a day before meals. The dosage may be adjusted according to your age and symptoms.Dosage of Aldorin 50 mgIn general, for adults, take 1 tablet (50 mg of the active ingredient) at a time, 3 times a day before meals. The dosage may be adjusted according to your age and symptoms.Interaction of Aldorin 50 mgThere are no known drug interactions and none well documented.Contraindications If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines. If you are pregnant or breastfeeding. If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) Side Effects of Aldorin 50 mgThe most commonly reported adverse reactions include abdominal pain, nausea, rash, itch, erythema and blister.Pregnancy & LactationPregnancy category is not classified. FDA has not yet classified the drug into a specified pregnancy categoryPrecautions & WarningsYour urinary color may turn yellowish brown or red due to color of the component of this medicine. Do not worry about the change.Storage ConditionsKeep out of the reach of children. Store away from direct sunlight, heat and moisture.Drug ClassesAldose reductase inhibitorMode Of ActionAldorin 50 mg is aldose reductase inhibitor. The aldose reductase inhibitors have a distinct mechanism of action, affecting the underlying disease process in diabetic neuropathy, although the extent of the polyol pathway involvement is yet to be determined. This medicine suppresses accumulation of sorbitol in cells by inhibiting action of aldose reductase which converts glucose of sugar to sorbitol. Aldorin 50 mg may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms.PregnancyPregnancy category is not classified. FDA has not yet classified the drug into a specified pregnancy category
Aldorin50 mg
Original price was: ₦6,050.00.₦5,505.50Current price is: ₦5,505.50.
18.08923
0.00005
0.00157
0.03729
4.13552
-
SaleAlercon DS 0.2%Olopatadine is indicated for the treatment of ocular itching associated with allergic conjunctivitis.Theropeutic ClassOphthalmic Non-Steroid drugsPharmacologyOlopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H1?antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in human, olopatadine was shown to have low systemic exposure.Dosage & Administration of Alercon DS 0.2%0.1% Sterile Eye Drops: One drop in each affected eye two times per day at an interval of 6 to 8 hours. 0.2% Sterile Eye Drops: One drop in the affected eye once a day.0.7% Sterile Eye Drops: One drop in each affected eye once a day.Interaction of Alercon DS 0.2%May result in additive CNS depression with CNS depressants.ContraindicationsAlercon DS 0.2% ophthalmic solution is contraindicated in persons with a known hypersensitivity to Alercon DS 0.2%.Side Effects of Alercon DS 0.2%Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: Asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversionPregnancy & LactationThere are no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the fetus.It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Alercon DS 0.2% ophthalmic solution is administered to a nursing mother.Precautions & WarningsOlopatadine HCl ophthalmic solution should not be used to treat contact lens related irritation. Patients who wear soft contact lenses should be instructed to wait at least ten minutes after instilling Alercon DS 0.2% ophthalmic solution before they insert their contact lenses.Overdose Effects of Alercon DS 0.2%Symptoms: Drowsiness in adults and, initially, agitation and restlessness, followed by drowsiness in childn. Management: Symptomatic or supportive treatment.Storage ConditionsStore below 30? C in a cool and dry place protected from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. Do not use after 30 days of first opening.Use In Special PopulationsGeriatric Use: No overall differences in safety or effectiveness have been observed betweents.
Alercon DS0.2%
Original price was: ₦8,800.00.₦7,920.00Current price is: ₦7,920.00.
26.02246
0.00007
0.00225
0.05364
5.94920
-
SaleAlestor 5 mgAlestor 5 mg is indicated in: Intra Uterine Growth Retardation (IUGR) Threatened abortion Habitual abortion Threatened premature delivery Theropeutic ClassFemale Sex hormonesPharmacologyAlestor 5 mg is a synthetic progesterone derivative that is used to treat threatened pregnancies. It can stop occurring premature labor and can help women give birth to a healthy newborn. It stimulates the secretory phase in myometrium, creates conditions for development of fertilized ovum. It has a tocolytic effect; reduces sensitivity of myometrium to oxytocin. It stimulates the development of acinus of mammary glands, secretory activity of trophoblasts, and development of aldosterone by adrenal glands. Alestor 5 mg also has a selection of ?-adrenergic effect. In this way, it stimulates the synthesis of the body's placental progesterone, therefore increasing the secretion of placental hormones.Dosage & Administration of Alestor 5 mgIntra Uterine Growth Retardation: 1 tablet three times a day at least two months. Dose to be reduced if symptoms improve. Threatened abortion: 1 tablet three times daily until symptoms disappear.Habitual abortion: 1-2 tablets daily as soon as pregnancy is diagnosed. The administration should be continued for at least one month after the end of the critical period.Threatened premature delivery: Dosage must be determined individually. High dosages (up to 40 mg daily) have been used.In case of a missed dose, it should be taken as soon as the patient remembers & she should continue the regular dosing schedule. A double dose is not recommended.Dosage of Alestor 5 mgIntra Uterine Growth Retardation: 1 tablet three times a day at least two months. Dose to be reduced if symptoms improve. Threatened abortion: 1 tablet three times daily until symptoms disappear.Habitual abortion: 1-2 tablets daily as soon as pregnancy is diagnosed. The administration should be continued for at least one month after the end of the critical period.Threatened premature delivery: Dosage must be determined individually. High dosages (up to 40 mg daily) have been used.In case of a missed dose, it should be taken as soon as the patient remembers & she should continue the regular dosing schedule. A double dose is not recommended.Contraindications Breast Cancer or history of problem with the breasts like- Nodules,an abnormal Mammogram, or Fibrocystic Diseases. Severe liver disease such as Cholestatic Jaundice or Hepatitis, Hepatic Cell Tumours, Rotor Syndrome and Dubin Jhonson Syndrome. Undiagnosed vaginal bleeding Toxaemia of Pregnancy Crisis Seizures, Migraines Side Effects of Alestor 5 mgTreatment with Alestor 5 mg (especially a long term treatment) is known to cause some gastrointestinal complaints such as vomiting, nausea, and sometimes epigastric discomfort.Pregnancy & LactationAlestor 5 mg is specifically designed to be taken during pregnancy. It should be discontinued after delivery as it may affect a nursing infant to a small but noticeable degree.Precautions & WarningsPatients with the following conditions should be cautious: Heart disease, congestive heart failure, sick sinus syndrome, coronary artery disease, seizures, epilepsy, renal dysfunction, migraine headaches, or breathing diseases including asthma, emphysema, chronic bronchitis, or COPD, breast-feeding.Overdose Effects of Alestor 5 mgSymptoms of overdose may include unusual drowsiness; rapid pulse; fainting; unusual muscle movement or rigidity of the face, neck, or limbs; seizures; and loss of consciousness.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsIt should not be used for children younger than 16 years old.Drug ClassesFemale Sex hormonesMode Of ActionAlestor 5 mg has been found to have a relatively weak progestational effect on the human endometrium. To obtain a full secretory endometrium in oestrogen-primed castrated women or to postpone menstruation (with an oestrogen added) in normal ovulating women, doses of Alestor 5 mg were required which were higher than those recommended for the treatment/prevention of abortion.In vitro studies have shown that Alestor 5 mg stimulates the synthesis of progesterone in the human placenta. It also brought about a significant (p/. 0,01) increase in the production of some specific placental enzymes (cystine aminopeptidase and heat-stable alkaline phosphatase).Histological and histochemical changes indicating an increased activity have been found in the placenta, particularly in the syncytiotrophoblast of women with a normal and threatened pregnancy, treated with Alestor 5 mg. The stimulatory effect of Alestor 5 mg on placental function was also suggested by the increased level of placental hormones (pregnanediol, oestriol, HCG and HPL) and enzymes (oxytocinase, CAP) in the maternal urine and plasma, which followed the administration of the drug e.g. in the early weeks as well as in the last trimester of pregnancy.A study in full-term pregnant women revealed that Alestor 5 mg in high doses (up to 100 mg daily) did suppress the intensity of spontaneous uterine contractions, but had no effect on the sensitivity of the uterine muscle to oxytocin, and no adverse effect on the progress of normal delivery.Studies in non-pregnant women with and without endocrinological disorders have shown that Alestor 5 mg has no oestrogenic or androgenic properties and no adverse effects on the adrenal function.No abnormal liver function tests or water and salt retention were observed in healthy female volunteers (non pregnant) who were given Alestor 5 mg.PregnancyAlestor 5 mg is specifically designed to be taken during pregnancy. It should be discontinued after delivery as it may affect a nursing infant to a small but noticeable degree.Pediatric UsesIt should not be used for children younger than 16 years old.
Alestor5 mg
Original price was: ₦4,400.00.₦3,960.00Current price is: ₦3,960.00.
13.01123
0.00004
0.00113
0.02682
2.97460
-
SaleAlexa 4000 Anti-Xa IU/0.4 mlEnoxaparin is indicated in: Treatment of deep vein thrombosis, with or without pulmonary embolism. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin. Prevention of thrombus formation in the extra-corporal circulation during haemodialysis. ... Read moreEnoxaparin is indicated in: Treatment of deep vein thrombosis, with or without pulmonary embolism. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin. Prevention of thrombus formation in the extra-corporal circulation during haemodialysis. Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins), in particular those which may be associated with orthopedic or general surgery. Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness, including cardiac insufficiency, respiratory failure, severe infections, rheumatic diseases. Composition Each 0.2 ml pre-filled syringe contains Alexa 4000 Anti-Xa IU/0.4 ml BP 20 mg equivalent to 2000 anti-Xa III. Each 0.4 ml pre-filled syringe contains Alexa 4000 Anti-Xa IU/0.4 ml BP 40 mg equivalent to 4000 anti-Xa III. Each 0.6 ml pre-filled syringe contains Alexa 4000 Anti-Xa IU/0.4 ml BP 60 mg equivalent to 6000 anti-Xa IU. Each 0.8 ml pre-filled syringe contains Alexa 4000 Anti-Xa IU/0.4 ml BP 80 mg equivalent to 8000 anti-Xa IU. Theropeutic ClassParenteral anti-coagulantsPharmacologyAlexa 4000 Anti-Xa IU/0.4 ml is a low molecular weight heparin with a high anti-Xa activity and low anti-lla or antithrombin activity. At doses required for the various indications, Alexa 4000 Anti-Xa IU/0.4 ml does not increase bleeding time. At preventive doses, Alexa 4000 Anti-Xa IU/0.4 ml causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Alexa 4000 Anti-Xa IU/0.4 ml is primarily metabolised in the liver.Dosage & Administration of Alexa 4000 Anti-Xa IU/0.4 mlTreatment of deep vein thrombosis, with or without pulmonary embolism: Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days or Subcutaneously 150 anti-Xa lU/kq once daily for 10 days. Oral anticoagulant therapy should be initiated when appropriate and Alexa 4000 Anti-Xa IU/0.4 ml treatment should be continued until a therapeutic anticoaqulant effect has been achieved. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin: Subcutaneously 100 anti-Xa lU/kg twice daily for 2- 8 days. Should be administered concurrently with oral aspirin (100 to 325 mg once daily). Treatment with Alexa 4000 Anti-Xa IU/0.4 ml in these patients should be prescribed fora minimum of 2 days and continued until clinical stabilization.Prevention of thrombus formation in extra corporeal circulation during hemodialysis: Recommended dose is 100 anti-Xa lU/kg. For patients with a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa lU/kg for double vascular access or 75 anti-Xa lU/kg for single vascular access. During hemodialysis, Alexa 4000 Anti-Xa IU/0.4 ml should be introduced into the arterial line of the circuit at the beqinninq of the dialysis session.Prophylaxis of venous thromboembolic disease in surgical patients: Patients undergoing general surgery with a moderate risk of thromboembolism (e.g. abdominal surgery): Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 2 hours before the surgical procedure. Patients undergoing orthopedic surgery with a high risk of thromboembolism: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 12 hours before the surgical procedure. Longer treatment duration may be appropriate in some patients like continued therapy with 4000 anti-Xa IU once daily for 3 weeks following the initial therapy has been proven to be beneficial in orthopaedic surqery. Prophylaxis of venous thromboembolic disease in medical patients: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6- 14 days. ?Dosage of Alexa 4000 Anti-Xa IU/0.4 mlTreatment of deep vein thrombosis, with or without pulmonary embolism: Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days or Subcutaneously 150 anti-Xa lU/kq once daily for 10 days. Oral anticoagulant therapy should be initiated when appropriate and Alexa 4000 Anti-Xa IU/0.4 ml treatment should be continued until a therapeutic anticoaqulant effect has been achieved. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin: Subcutaneously 100 anti-Xa lU/kg twice daily for 2- 8 days. Should be administered concurrently with oral aspirin (100 to 325 mg once daily). Treatment with Alexa 4000 Anti-Xa IU/0.4 ml in these patients should be prescribed fora minimum of 2 days and continued until clinical stabilization.Prevention of thrombus formation in extra corporeal circulation during hemodialysis: Recommended dose is 100 anti-Xa lU/kg. For patients with a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa lU/kg for double vascular access or 75 anti-Xa lU/kg for single vascular access. During hemodialysis, Alexa 4000 Anti-Xa IU/0.4 ml should be introduced into the arterial line of the circuit at the beqinninq of the dialysis session.Prophylaxis of venous thromboembolic disease in surgical patients: Patients undergoing general surgery with a moderate risk of thromboembolism (e.g. abdominal surgery): Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 2 hours before the surgical procedure. Patients undergoing orthopedic surgery with a high risk of thromboembolism: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 12 hours before the surgical procedure. Longer treatment duration may be appropriate in some patients like continued therapy with 4000 anti-Xa IU once daily for 3 weeks following the initial therapy has been proven to be beneficial in orthopaedic surqery. Prophylaxis of venous thromboembolic disease in medical patients: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6- 14 days.Administration of Alexa 4000 Anti-Xa IU/0.4 mlInstructions on injecting yourself with Alexa 4000 Anti-Xa IU/0.4 ml Syringes: Preparing the injection site: Choose an area on the right or left side of your stomach. This should be at least 5 centimeters away from your belly button and out towards your sides. Do not inject yourself within 5cm of your belly button or around existing scars or bruises. Change the place where you inject between the left and right sides of your stomach, depending on the area you last injected. Wash your hands. Cleanse (do not rub) the area that you will inject with an alcohol swab or soap and water. Sit or lie in a comfortable position so that you are relaxed. Make sure you can see the place you are going to inject. A lounge chair, recliner, or bed propped up with pillows is ideal. Selecting your dose: Carefully pull off the needle cap from the syringe. Throw away the cap. Do not press on the plunger before injecting yourself to get rid of air bubbles. This can lead to a loss of the medicine. Once you have removed the cap, do not allow the needle to touch anything. This is to make sure the needle stays clean (sterile). When the amount of medication in the syringe matches your prescribed dose, there is no need to adjust the dose. You are now ready to inject. When the dose depends on your body weight, you may need to adjust the dose in the syringe to match the prescribed dose. In that case, you can get rid of any extra medicine by holding the syringe pointing down (to keep the air bubble in the syringe) and ejecting the extra amount into a container. A drop may appear at the tip of the needle. If this occurs, remove the drop before injecting by tapping on the syringe with the needle pointing down. You are now ready to inject. Injecting: Hold the syringe in the hand you write with (like a pencil). With your other hand, gently pinch the cleaned area of your stomach between your forefinger and thumb to make a fold in the skin. Make sure you hold the skin fold throughout the injection. Hold the syringe so that the needle is point in straight down (vertically at a 90? angle). Insert the full length of the needle into the skin fold. Press down on the plunger with your thumb. This will send the medication into the fatty tissue of the stomach. Complete the injection using all of the medicine in the syringe. When you have finished: To avoid bruising, do not rub the injection site after you have injected yourself. Drop the used syringe into a sharps container. Close the container lid tightly and place the container out of reach of the children. When the container is full, dispose of it as your doctor or pharmacist has instructed. Any unused medicine or waste material should be disposed of in accordance with local requirements. Interaction of Alexa 4000 Anti-Xa IU/0.4 mlIt is recommended that agents which affect hemostasis should be discontinued prior to Alexa 4000 Anti-Xa IU/0.4 ml therapy unless strictly indicated. These agents include medications such as: acetylsalicylic acid (and derivatives), NSAIDs (including ketorolac), ticlopidine,clopidogrel,dextran 40,glucocorticoids, thrombolytics and anticoagulants, other antiplatelet aggregation agents including glycoprotein llb/llla antagonists. If the combination is indicated, should be used with careful clinical and laboratory monitoring.ContraindicationsPatients with known hypersensitivity to Alexa 4000 Anti-Xa IU/0.4 ml, heparin or other low molecular weight heparins. Patients with active major bleeding and conditions with a high risk of uncontrolled hemorrhage including recent hemorrhagic stroke.Side Effects of Alexa 4000 Anti-Xa IU/0.4 mlHaemorrhage (bleeding), Thrombocytopenia, elevations of serum aminotransferase. Pain, bluish marks at injection sites to skin rash at injection sites. Cases of neuraxial hematomas with the concurrent use of Enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries.Pregnancy & LactationPregnancy category B. In humans, there is no evidence that Alexa 4000 Anti-Xa IU/0.4 ml crosses the placental barrier. As there are no adequate and well-controlled studies in pregnant women, Alexa 4000 Anti-Xa IU/0.4 ml should be used during pregnancy only if clearly needed. Pregnant women with mechanical prosthetic heart valves may be at a higher risk for thromboembolism.It is not known whether Enoxaparin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing.Precautions & WarningsAlexa 4000 Anti-Xa IU/0.4 ml should be injected by deep subcutaneous route in prophylactic and curative treatment and by intravascular route during hemodialysis. Do not administer by the intramuscular route. Alexa 4000 Anti-Xa IU/0.4 ml should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy and recent neuro- or ophthalmologic surgery, concomitant use of medications affecting hemostasis. It is recommended that the platelet counts be measured before the initiation of the treatment and regularly thereafter during treatment.Overdose Effects of Alexa 4000 Anti-Xa IU/0.4 mlAccidental overdosage following administration of Enoxaparin may lead to hemorrhagic complications. Injected Enoxaparin may be largely neutralized by the slow i.v. injection of protamine sulfate (1% solution) The dose of protamine sulfate should be equal to the dose of Enoxaparin injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Enoxaparin.Storage ConditionsStore in a cool and dry place, protect from light and moisture. Do not store above 25?C. Do not store in a refrigerator or freezer. Keep out of the reach of childrenUse In Special PopulationsDose in Elderly Patients: No dosage adjustment is necessary, unless kidney function is impaired.Dose in Renal Impairment: Although no dosage adjustment is recommended in patients with moderate (creatinine clearance: 30-50 ml/min) and mild (creatinine clearance: 50 80 ml/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding. For patients with severe (creatinine clearance <30 ml/min) renal impairment, following dosage adjustments are recommended: Prophylactic dose ranges: 2000 antiXa IU once daily; Therapeutic dose ranges: 100 anti-Xa lU/kg once daily.Dose in Hepatic Impairment: Caution should be used in hepatically impaired patients.Drug ClassesParenteral anti-coagulantsMode Of ActionAlexa 4000 Anti-Xa IU/0.4 ml is a low molecular weight heparin with a high anti-Xa activity and low anti-lla or antithrombin activity. At doses required for the various indications, Alexa 4000 Anti-Xa IU/0.4 ml does not increase bleeding time. At preventive doses, Alexa 4000 Anti-Xa IU/0.4 ml causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Alexa 4000 Anti-Xa IU/0.4 ml is primarily metabolised in the liver.PregnancyPregnancy category B. In humans, there is no evidence that Alexa 4000 Anti-Xa IU/0.4 ml crosses the placental barrier. As there are no adequate and well-controlled studies in pregnant women, Alexa 4000 Anti-Xa IU/0.4 ml should be used during pregnancy only if clearly needed. Pregnant women with mechanical prosthetic heart valves may be at a higher risk for thromboembolism.It is not known whether Enoxaparin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing.Pediatric UsesDose in Elderly Patients: No dosage adjustment is necessary, unless kidney function is impaired.Dose in Renal Impairment: Although no dosage adjustment is recommended in patients with moderate (creatinine clearance: 30-50 ml/min) and mild (creatinine clearance: 50 80 ml/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding. For patients with severe (creatinine clearance <30 ml/min) renal impairment, following dosage adjustments are recommended: Prophylactic dose ranges: 2000 antiXa IU once daily; Therapeutic dose ranges: 100 anti-Xa lU/kg once daily.Dose in Hepatic Impairment: Caution should be used in hepatically impaired patients.
Alexa4000 Anti-Xa IU/0.4 ml
Original price was: ₦24,750.00.₦22,770.00Current price is: ₦22,770.00.
74.81458
0.00021
0.00648
0.15422
17.10394
-
SaleAlexa 6000 Anti-Xa IU/0.6 mlEnoxaparin is indicated in: Treatment of deep vein thrombosis, with or without pulmonary embolism. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin. Prevention of thrombus formation in the extra-corporal circulation during haemodialysis. ... Read moreEnoxaparin is indicated in: Treatment of deep vein thrombosis, with or without pulmonary embolism. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin. Prevention of thrombus formation in the extra-corporal circulation during haemodialysis. Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins), in particular those which may be associated with orthopedic or general surgery. Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness, including cardiac insufficiency, respiratory failure, severe infections, rheumatic diseases. Composition Each 0.2 ml pre-filled syringe contains Alexa 6000 Anti-Xa IU/0.6 ml BP 20 mg equivalent to 2000 anti-Xa III. Each 0.4 ml pre-filled syringe contains Alexa 6000 Anti-Xa IU/0.6 ml BP 40 mg equivalent to 4000 anti-Xa III. Each 0.6 ml pre-filled syringe contains Alexa 6000 Anti-Xa IU/0.6 ml BP 60 mg equivalent to 6000 anti-Xa IU. Each 0.8 ml pre-filled syringe contains Alexa 6000 Anti-Xa IU/0.6 ml BP 80 mg equivalent to 8000 anti-Xa IU. Theropeutic ClassParenteral anti-coagulantsPharmacologyAlexa 6000 Anti-Xa IU/0.6 ml is a low molecular weight heparin with a high anti-Xa activity and low anti-lla or antithrombin activity. At doses required for the various indications, Alexa 6000 Anti-Xa IU/0.6 ml does not increase bleeding time. At preventive doses, Alexa 6000 Anti-Xa IU/0.6 ml causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Alexa 6000 Anti-Xa IU/0.6 ml is primarily metabolised in the liver.Dosage & Administration of Alexa 6000 Anti-Xa IU/0.6 mlTreatment of deep vein thrombosis, with or without pulmonary embolism: Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days or Subcutaneously 150 anti-Xa lU/kq once daily for 10 days. Oral anticoagulant therapy should be initiated when appropriate and Alexa 6000 Anti-Xa IU/0.6 ml treatment should be continued until a therapeutic anticoaqulant effect has been achieved. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin: Subcutaneously 100 anti-Xa lU/kg twice daily for 2- 8 days. Should be administered concurrently with oral aspirin (100 to 325 mg once daily). Treatment with Alexa 6000 Anti-Xa IU/0.6 ml in these patients should be prescribed fora minimum of 2 days and continued until clinical stabilization.Prevention of thrombus formation in extra corporeal circulation during hemodialysis: Recommended dose is 100 anti-Xa lU/kg. For patients with a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa lU/kg for double vascular access or 75 anti-Xa lU/kg for single vascular access. During hemodialysis, Alexa 6000 Anti-Xa IU/0.6 ml should be introduced into the arterial line of the circuit at the beqinninq of the dialysis session.Prophylaxis of venous thromboembolic disease in surgical patients: Patients undergoing general surgery with a moderate risk of thromboembolism (e.g. abdominal surgery): Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 2 hours before the surgical procedure. Patients undergoing orthopedic surgery with a high risk of thromboembolism: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 12 hours before the surgical procedure. Longer treatment duration may be appropriate in some patients like continued therapy with 4000 anti-Xa IU once daily for 3 weeks following the initial therapy has been proven to be beneficial in orthopaedic surqery. Prophylaxis of venous thromboembolic disease in medical patients: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6- 14 days. ?Dosage of Alexa 6000 Anti-Xa IU/0.6 mlTreatment of deep vein thrombosis, with or without pulmonary embolism: Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days or Subcutaneously 150 anti-Xa lU/kq once daily for 10 days. Oral anticoagulant therapy should be initiated when appropriate and Alexa 6000 Anti-Xa IU/0.6 ml treatment should be continued until a therapeutic anticoaqulant effect has been achieved. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin: Subcutaneously 100 anti-Xa lU/kg twice daily for 2- 8 days. Should be administered concurrently with oral aspirin (100 to 325 mg once daily). Treatment with Alexa 6000 Anti-Xa IU/0.6 ml in these patients should be prescribed fora minimum of 2 days and continued until clinical stabilization.Prevention of thrombus formation in extra corporeal circulation during hemodialysis: Recommended dose is 100 anti-Xa lU/kg. For patients with a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa lU/kg for double vascular access or 75 anti-Xa lU/kg for single vascular access. During hemodialysis, Alexa 6000 Anti-Xa IU/0.6 ml should be introduced into the arterial line of the circuit at the beqinninq of the dialysis session.Prophylaxis of venous thromboembolic disease in surgical patients: Patients undergoing general surgery with a moderate risk of thromboembolism (e.g. abdominal surgery): Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 2 hours before the surgical procedure. Patients undergoing orthopedic surgery with a high risk of thromboembolism: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given 12 hours before the surgical procedure. Longer treatment duration may be appropriate in some patients like continued therapy with 4000 anti-Xa IU once daily for 3 weeks following the initial therapy has been proven to be beneficial in orthopaedic surqery. Prophylaxis of venous thromboembolic disease in medical patients: Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6- 14 days.Administration of Alexa 6000 Anti-Xa IU/0.6 mlInstructions on injecting yourself with Alexa 6000 Anti-Xa IU/0.6 ml Syringes: Preparing the injection site: Choose an area on the right or left side of your stomach. This should be at least 5 centimeters away from your belly button and out towards your sides. Do not inject yourself within 5cm of your belly button or around existing scars or bruises. Change the place where you inject between the left and right sides of your stomach, depending on the area you last injected. Wash your hands. Cleanse (do not rub) the area that you will inject with an alcohol swab or soap and water. Sit or lie in a comfortable position so that you are relaxed. Make sure you can see the place you are going to inject. A lounge chair, recliner, or bed propped up with pillows is ideal. Selecting your dose: Carefully pull off the needle cap from the syringe. Throw away the cap. Do not press on the plunger before injecting yourself to get rid of air bubbles. This can lead to a loss of the medicine. Once you have removed the cap, do not allow the needle to touch anything. This is to make sure the needle stays clean (sterile). When the amount of medication in the syringe matches your prescribed dose, there is no need to adjust the dose. You are now ready to inject. When the dose depends on your body weight, you may need to adjust the dose in the syringe to match the prescribed dose. In that case, you can get rid of any extra medicine by holding the syringe pointing down (to keep the air bubble in the syringe) and ejecting the extra amount into a container. A drop may appear at the tip of the needle. If this occurs, remove the drop before injecting by tapping on the syringe with the needle pointing down. You are now ready to inject. Injecting: Hold the syringe in the hand you write with (like a pencil). With your other hand, gently pinch the cleaned area of your stomach between your forefinger and thumb to make a fold in the skin. Make sure you hold the skin fold throughout the injection. Hold the syringe so that the needle is point in straight down (vertically at a 90? angle). Insert the full length of the needle into the skin fold. Press down on the plunger with your thumb. This will send the medication into the fatty tissue of the stomach. Complete the injection using all of the medicine in the syringe. When you have finished: To avoid bruising, do not rub the injection site after you have injected yourself. Drop the used syringe into a sharps container. Close the container lid tightly and place the container out of reach of the children. When the container is full, dispose of it as your doctor or pharmacist has instructed. Any unused medicine or waste material should be disposed of in accordance with local requirements. Interaction of Alexa 6000 Anti-Xa IU/0.6 mlIt is recommended that agents which affect hemostasis should be discontinued prior to Alexa 6000 Anti-Xa IU/0.6 ml therapy unless strictly indicated. These agents include medications such as: acetylsalicylic acid (and derivatives), NSAIDs (including ketorolac), ticlopidine,clopidogrel,dextran 40,glucocorticoids, thrombolytics and anticoagulants, other antiplatelet aggregation agents including glycoprotein llb/llla antagonists. If the combination is indicated, should be used with careful clinical and laboratory monitoring.ContraindicationsPatients with known hypersensitivity to Alexa 6000 Anti-Xa IU/0.6 ml, heparin or other low molecular weight heparins. Patients with active major bleeding and conditions with a high risk of uncontrolled hemorrhage including recent hemorrhagic stroke.Side Effects of Alexa 6000 Anti-Xa IU/0.6 mlHaemorrhage (bleeding), Thrombocytopenia, elevations of serum aminotransferase. Pain, bluish marks at injection sites to skin rash at injection sites. Cases of neuraxial hematomas with the concurrent use of Enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries.Pregnancy & LactationPregnancy category B. In humans, there is no evidence that Alexa 6000 Anti-Xa IU/0.6 ml crosses the placental barrier. As there are no adequate and well-controlled studies in pregnant women, Alexa 6000 Anti-Xa IU/0.6 ml should be used during pregnancy only if clearly needed. Pregnant women with mechanical prosthetic heart valves may be at a higher risk for thromboembolism.It is not known whether Enoxaparin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing.Precautions & WarningsAlexa 6000 Anti-Xa IU/0.6 ml should be injected by deep subcutaneous route in prophylactic and curative treatment and by intravascular route during hemodialysis. Do not administer by the intramuscular route. Alexa 6000 Anti-Xa IU/0.6 ml should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy and recent neuro- or ophthalmologic surgery, concomitant use of medications affecting hemostasis. It is recommended that the platelet counts be measured before the initiation of the treatment and regularly thereafter during treatment.Overdose Effects of Alexa 6000 Anti-Xa IU/0.6 mlAccidental overdosage following administration of Enoxaparin may lead to hemorrhagic complications. Injected Enoxaparin may be largely neutralized by the slow i.v. injection of protamine sulfate (1% solution) The dose of protamine sulfate should be equal to the dose of Enoxaparin injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Enoxaparin.Storage ConditionsStore in a cool and dry place, protect from light and moisture. Do not store above 25?C. Do not store in a refrigerator or freezer. Keep out of the reach of childrenUse In Special PopulationsDose in Elderly Patients: No dosage adjustment is necessary, unless kidney function is impaired.Dose in Renal Impairment: Although no dosage adjustment is recommended in patients with moderate (creatinine clearance: 30-50 ml/min) and mild (creatinine clearance: 50 80 ml/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding. For patients with severe (creatinine clearance <30 ml/min) renal impairment, following dosage adjustments are recommended: Prophylactic dose ranges: 2000 antiXa IU once daily; Therapeutic dose ranges: 100 anti-Xa lU/kg once daily.Dose in Hepatic Impairment: Caution should be used in hepatically impaired patients.Drug ClassesParenteral anti-coagulantsMode Of ActionAlexa 6000 Anti-Xa IU/0.6 ml is a low molecular weight heparin with a high anti-Xa activity and low anti-lla or antithrombin activity. At doses required for the various indications, Alexa 6000 Anti-Xa IU/0.6 ml does not increase bleeding time. At preventive doses, Alexa 6000 Anti-Xa IU/0.6 ml causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Alexa 6000 Anti-Xa IU/0.6 ml is primarily metabolised in the liver.PregnancyPregnancy category B. In humans, there is no evidence that Alexa 6000 Anti-Xa IU/0.6 ml crosses the placental barrier. As there are no adequate and well-controlled studies in pregnant women, Alexa 6000 Anti-Xa IU/0.6 ml should be used during pregnancy only if clearly needed. Pregnant women with mechanical prosthetic heart valves may be at a higher risk for thromboembolism.It is not known whether Enoxaparin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing.Pediatric UsesDose in Elderly Patients: No dosage adjustment is necessary, unless kidney function is impaired.Dose in Renal Impairment: Although no dosage adjustment is recommended in patients with moderate (creatinine clearance: 30-50 ml/min) and mild (creatinine clearance: 50 80 ml/min) renal impairment, all such patients should be observed carefully for signs and symptoms of bleeding. For patients with severe (creatinine clearance <30 ml/min) renal impairment, following dosage adjustments are recommended: Prophylactic dose ranges: 2000 antiXa IU once daily; Therapeutic dose ranges: 100 anti-Xa lU/kg once daily.Dose in Hepatic Impairment: Caution should be used in hepatically impaired patients.
Alexa6000 Anti-Xa IU/0.6 ml
Original price was: ₦35,750.00.₦32,890.00Current price is: ₦32,890.00.
108.06551
0.00030
0.00936
0.22276
24.70569
-
Sale
Alfacon600 mg
Original price was: ₦22,000.00.₦20,240.00Current price is: ₦20,240.00.
66.50185
0.00019
0.00576
0.13708
15.20350
-
SaleAlfacort 40 mg/mlPost-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis, acute and sub-acute bursitis, epicondylitis, acute non-specific tenosynovitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis, bronchial asthma, contact dermatitis, atopic dermatitis, seasonal or perennial allergic rhinitis.Theropeutic ClassCorticosteroid, Glucocorticoids, Triamcinolone & Combined preparationsPharmacologyThe antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.Dosage & Administration of Alfacort 40 mg/mlAdults and children over 12 years of age: Initial dose is 60 mg. Dosage is usually adjusted within the range of 40 to 80 mg. For local areas, dose for adults is up to 10 mg for smaller areas and up to 40 mg for larger areas.Children 6 to 12 years: Initial dose is 40 mgInteraction of Alfacort 40 mg/mlAminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.?Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.?Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.?Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.?Anticoagulants, oral: Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.?Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.?Antitubercular drugs: Serum concentrations of isoniazid may be decreased.?Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.?Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.?Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.?Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.?Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.?Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.?Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.?Skin tests: Corticosteroids may suppress reactions to skin tests.?Vaccines: Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.ContraindicationsAlfacort 40 mg/ml injection is contraindicated in patients with a sensitivity to the active or inactive ingredients.Side Effects of Alfacort 40 mg/mlCushingoid syndrome, weakness, bruising or purpura, aggravation of infections, peptic ulcer, activation of latent or aggravation of existing diabetes, altered menstrual cycle, hirsutism.Pregnancy & LactationAlfacort 40 mg/ml injection should be used during pregnancy, nursing mothers if the possible benefits of the medication justify the potential hazards to the fetus or nursing infant.Precautions & WarningsAlfacort 40 mg/ml injection should be used cautiously in patients with ocular herpes simplex, nonspecific ulcerative colitis, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, Cushing's syndrome, diabetes mellitus, congestive heart failure, chronic nephritis.Overdose Effects of Alfacort 40 mg/mlTreatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.Storage ConditionsStore at controlled room temperature, 20?25 ?C, avoid freezing and protect from light.
Alfacort40 mg/ml
Original price was: ₦3,300.00.₦2,970.00Current price is: ₦2,970.00.
9.75842
0.00003
0.00085
0.02012
2.23095
-
SaleAlfavir 25 mgAlfavir 25 mg is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.Theropeutic ClassHepatic viral infections (Hepatitis B)PharmacologyTenofovir alafenamide is a phosphonamidate?prodrug?of tenofovir (2'-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits?HBV?replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination.Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include?mitochondrial DNA polymerase ? and there is no evidence of toxicity to?mitochondria?in cell culture.Dosage & Administration of Alfavir 25 mgTesting Prior To Initiation Of Alfavir 25 mg: Prior to initiation of Alfavir 25 mg, patients should be tested for?HIV-1 infection. Alfavir 25 mg alone should not be used in patients with HIV infectionIt is recommended that serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating Alfavir 25 mg and during therapy in all patients as clinically appropriateRecommended Dosage In Adults: The recommended dosage of Alfavir 25 mg is 25 mg (one tablet) taken orally once daily with foodDosage of Alfavir 25 mgTesting Prior to Initiation of Tenofovir alafenamide:?Prior to initiation of Tenofovir alafenamide, patients should be tested for HIV-1 infection. Tenofovir alafenamide alone should not be used in patients with HIV-1 infection.Recommended Dosage in Adults:?The recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food.Dosage in Patients with Renal Impairment: No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute or in patients with end stage renal disease (ESRD; estimated creatinine clearance below 15 ml per minute) who are receiving chronic hemodialysis. On days of hemodialysis administer Tenofovir alafenamide after completion of hemodialysis treatment. Tenofovir alafenamide is not recommended in patients with ESRD who are not receiving chronic hemodialysis.Dosage in Patients with Hepatic Impairment:?No dosage adjustment of Tenofovir alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.Pediatric Use:?Safety and effectiveness of Tenofovir alafenamide in pediatric patients less than 18 years of age have not been established.Geriatric Use:?In clinical trials, Tenofovir alafenamide was administered to 89 subjects aged 65 and over. No clinically significant differences in safety or efficacy have been observed between elderly subjects and subjects between 18 and less than 65 years of age.Interaction of Alfavir 25 mgPotential for Other Drugs to Affect Tenofovir alafenamide:?Tenofovir alafenamide is a substrate of P-glycoprotein (P-gp) and BCRP. Drugs that strongly affect P-gp and BCRP activity may lead to changes in Alfavir 25 mg absorption. Drugs that induce P-gp activity are expected to decrease the absorption of Alfavir 25 mg resulting in decreased plasma concentrations of Alfavir 25 mg which may lead to loss of therapeutic effect of Tenofovir alafenamide. Coadministration of Tenofovir alafenamide with other drugs that inhibit P-gp and BCRP may increase the absorption & plasma concentration of Alfavir 25 mg.Drugs Affecting Renal Function: Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of Tenofovir alafenamide with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include but are not limited to acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin) and high-dose or multiple NSAIDs.ContraindicationsNoneSide Effects of Alfavir 25 mgThe following adverse reactions are discussed in other sections of the labeling: Lactic Acidosis/Severe?Hepatomegaly?with Steatosis? Severe Acute Exacerbation of?Hepatitis B New Onset or Worsening of Renal Impairment The most common side effects are headache, stomach pain, tiredness, cough, nausea, back painPregnancy & LactationBefore you take Alfavir 25 mg, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant. It is not known if Alfavir 25 mg will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with Alfavir 25 mg.?Pregnancy Registry:?There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.Precautions & WarningsSevere Acute Exacerbation of Hepatitis B after Discontinuation of Treatment: Discontinuation of anti-hepatitis B therapy, including Tenofovir alafenamide may result in severe acute exacerbations of hepatitis B. Patients who discontinue Tenofovir alafenamide should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate resumption of antihepatitis B therapy may be warranted.Risk of Development of HIV-1 Resistance in Patients Coinfected with HBV and HIV-1:?Due to the risk of development of HIV-1 resistance Tenofovir alafenamide alone is not recommended for the treatment of HIV-1 infection. The safety and efficacy of Tenofovir alafenamide have not been established in patients coinfected with HBV and HIV-1. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with Tenofovir alafenamide and if positive, an appropriate antiretroviral combination regimen that is recommended for patients coinfected with HIV-1 should be used.New Onset or Worsening Renal Impairment:?Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT) and Fanconi syndrome have been reported with TAF-containing products; while most of these cases were characterized by potential confounders that may have contributed to the reported renal events, it is also possible these factors may have predisposed patients to tenofovir- related adverse events. Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents, including non-steroidal anti-inflammatory drugs, are at increased risk of developing renal-related adverse reactions. Prior to or when initiating Tenofovir alafenamide and during treatment with Tenofovir alafenamide on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue Tenofovir alafenamide in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.Lactic Acidosis/Severe Hepatomegaly with Steatosis:?Lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported with the use of nucleoside analogs including tenofovir disoproxil fumarate (TDF) another prodrug of tenofovir alone or in combination with other antiretrovirals. Treatment with Tenofovir alafenamide should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).Overdose Effects of Alfavir 25 mgIf overdose occurs, monitor patient for evidence of toxicity. Treatment of overdosage with Tenofovir alafenamide consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Tenofovir is efficiently removed by hemo- dialysis with an extraction coefficient of approximately 54%.Storage ConditionsStore below 30?C. Keep it in its original container. protect from light. Keep out of children?s reach.Use In Special PopulationsPediatric Use: Safety and effectiveness of Alfavir 25 mg in pediatric patients less than 18 years of age have not been established.Geriatric Use: Clinical trials of Alfavir 25 mg did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.Renal Impairment: No dosage adjustment of Alfavir 25 mg is required in patients with mild, moderate, or severe renal impairment. Alfavir 25 mg is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL per minute)?Hepatic Impairment: No dosage adjustment of Alfavir 25 mg is required in patients with mild hepatic impairment (Child-Pugh A). The safety and efficacy of Alfavir 25 mg in patients with decompensated cirrhosis (Child-Pugh B or C) have not been established; therefore Alfavir 25 mg is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairmentDrug ClassesHepatic viral infections (Hepatitis B)Mode Of ActionTenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2?-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase ? and there is no evidence of toxicity to mitochondria in cell culture.PregnancyPregnancy:?Based on prospective reports to the APR of over 660 exposures to TAF-containing regimens during pregnancy resulting in live births (including over 520 exposed in the first trimester and over 130 exposed in the second/third trimester), the prevalence of birth defects in live births was 4.2% (95% CI: 2.6% to 6.3%) and 3.0% (95% CI: 0.8% to 7.5%) following first and second/third trimester exposure, respectively, to TAF-containing regimens. Methodologic limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates women and infants from a limited geographic area, and does not include outcomes for births that occurred at less than 20 weeks gestation.Lactation: It is not known whether Tenofovir alafenamide & its metabolites are present in human breast milk, affect human milk production or have effects on the breastfed infant. Tenofovir has been shown to be present in the milk of lactating rats and rhesus monkeys after administration of TDF. It is not known if Alfavir 25 mg can be present in animal milk. The developmental and health benefits of breastfeeding should be considered along with the mother?s clinical need for Tenofovir alafenamide and any potential adverse effects on the breastfed infant from Tenofovir alafenamide or from the underlying maternal condition.
Alfavir25 mg
Original price was: ₦49,500.00.₦44,550.00Current price is: ₦44,550.00.
146.37636
0.00041
0.01268
0.30173
33.46423
-
SaleAlfumax-ER 10 mgAlfumax-ER 10 mg is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH), lower urinary tract symptoms (LUTS) including urinary frequency, nocturia, incomplete emptying and urinary hesitancy associated with BPH.Theropeutic ClassBPH/ Urinary retention/ Urinary incontinencePharmacologyAlfumax-ER 10 mg is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfumax-ER 10 mg relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfumax-ER 10 mg preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.Dosage of Alfumax-ER 10 mgBenign prostatic hyperplasia (BPH): The recommended dose is 10 mg to be taken once daily after a meal. Acute urinary retention (AUR): In patients 65 years and older, 10 mg? daily after a meal to be taken from the first day of catheterisation. The treatment should be administered for 3-4 days, 2-3 days during catheterisation and 1 day after its removal. In this indication no benefit has been established in patients under 65 years of age or if treatment is extended beyond 4 days.Administration of Alfumax-ER 10 mgAlfumax-ER 10 mg tablet should be swallowed whole.Interaction of Alfumax-ER 10 mgCombinations contra-indicated: Alpha-1-receptor blockers. Combinations to be taken into account: Antihypertensive drugs, nitrates, potent CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir. Repeated 200mg daily dosing of ketoconazole, for seven days resulted in a 2.1-fold increase in Cmax and a 2.5-fold increase in exposure of Alfumax-ER 10 mg 10mg when administered as a single dose under fed conditions (high fat meal). Other parameters such as tmax and t1/2 were not modified. Cmax and AUC of Alfumax-ER 10 mg 10mg, when administered as a single dose under fed conditions, increased 2.3- fold and 3.0- fold, respectively following 8-day repeated 400mg ketoconazole daily dosing. The administration of general anaesthetics to patients receiving Alfumax-ER 10 mg could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery.Other forms of interaction:?No pharmacodynamic or pharmacokinetic interaction has been observed in healthy volunteers between Alfumax-ER 10 mg and the following drugs: warfarin, digoxin, hydrochlorothiazide and atenolol.ContraindicationsAs with all alpha-1-blockers in some subjects, in particular patients receiving antihypertensive medications or nitrates, postural hypotension with or without symptoms (dizziness, fatigue, sweating) may develop within a few hours following administration. In such cases, the patient should lie down until the symptoms have completely disappeared. These effects are transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. The patient should be warned of the possible occurrence of such events. As with all alpha1-receptor blockers, Alfumax-ER 10 mg should be used with caution in patients with acute cardiac failure. Care should be taken when Alfumax-ER 10 mg is administered to patients who have had a pronounced hypotensive response to another alpha-1-blocker. Treatment should be initiated gradually in patients with hypersensitivity to alpha-1-blockers. Alfumax-ER 10 mg should be administered carefully to patients being treated with antihypertensives. Blood pressure should be monitored regularly, especially at the beginning of treatment. Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of Alfumax-ER 10 mg. In coronary patients, the specific treatment for coronary insufficiency should be continued. If angina pectoris reappears or worsens Alfumax-ER 10 mg should be discontinued.? As there are no clinical safety data available in patients with severe renal impairment (creatinine clearance < 30ml/min), Alfumax-ER 10 mg 10mg prolonged released tablets should not be administered to this patient group. Patients should be warned that the tablet should be swallowed whole. Any other mode of administration, such as crunching, crushing, chewing, grinding or pounding to powder should be prohibited. These actions may lead to inappropriate release and absorption of the drug and therefore possible early adverse reactions. The ?Intraoperative Floppy Iris Syndrome? (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with alpha-1-blockers. Although the risk of this event with Alfumax-ER 10 mg appears very low, ophthalmic surgeons should be informed in advance of cataract surgery of current or past use of alpha-1-blockers, as IFIS may lead to increased procedural complications. The ophthalmologists should be prepared for possible modifications to their surgical technique. Alfumax-ER 10 mg 10mg prolonged release tablets contain hydrogenated castor oil which may cause stomach upset and diarrhoea.Side Effects of Alfumax-ER 10 mgClassification of expected frequencies: Very common (<1/10), common (<1/100 to <1/10), uncommon (<1/1,000 to <1/100), rare (<1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Nervous system disorders: Common: faintness/dizziness, headache; Uncommon: syncope, vertigo, malaise, drowsiness. Eye disorders: Uncommon: vision abnormal; Not known: intraoperative floppy iris syndrome. Cardiac disorders: Uncommon: tachycardia, palpitations, hypotension (postural); Very rare: New onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; Not known: atrial fibrillation. Vascular disorders: Uncommon: hypotension (postural), flushing. Blood and lymphatic system disorders: Not known: neutropenia, thrombocytopenia. Respiratory, thoracic and mediastinal disorders: Uncommon: rhinitis. Gastro-intestinal disorders: Common: nausea, abdominal pain; Uncommon: diarrhoea, dry mouth, vomiting; Not known: vomiting. Hepatobiliary disorders: Frequency unknown: hepatocellular injury, cholestatic liver disease. Skin and subcutaneous tissue disorders: Uncommon: rash, pruritus; Very rare: urticaria, angioedema. Reproductive system and breast disorders: Frequency unknown: priapism. General disorders and administration site conditions: Common: asthenia; Uncommon: flushes, oedema, chest pain.Pregnancy & LactationDue to the type of indication this is not applicable.Precautions & WarningsThe administration of general anesthetics to patients receiving Alfuzosin could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery. If symptoms of angina pectoris start or get worse, taking Alfuzosin should be stopped.Overdose Effects of Alfumax-ER 10 mgIn case of overdosage, the patient should be hospitalised, kept in the supine position, and conventional treatment of hypotension should take place. In case of significant hypotension, the appropriate corrective treatment may be a vasoconstrictor that acts directly on vascular muscle fibres.Storage ConditionsStore in a cool and dry place, protected from lightUse In Special PopulationsPaediatric Population: Efficacy of Alfumax-ER 10 mg has not been demonstrated in children aged 2 to 16 years. Therefore Alfumax-ER 10 mg is not indicated for use in the paediatric population.Drug ClassesBPH/ Urinary retention/ Urinary incontinenceMode Of ActionAlfumax-ER 10 mg is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfumax-ER 10 mg relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfumax-ER 10 mg preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.PregnancyDue to the type of indication this is not applicable.Pediatric UsesPaediatric Population: Efficacy of Alfumax-ER 10 mg has not been demonstrated in children aged 2 to 16 years. Therefore Alfumax-ER 10 mg is not indicated for use in the paediatric population.
Alfumax-ER10 mg
Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00.
16.26404
0.00005
0.00141
0.03353
3.71825
-
SaleAlgin 100 mlAlgin 100 ml is an antispasmodic drug that reduces muscles spasm of the intestine, biliary system, bladder and uterus. It is used in symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system. It is also indicated for the treatment of spasm and pain in urological and gynaecological diseases.Theropeutic ClassAnticholinergicsPharmacologyAlgin 100 ml a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.Dosage & Administration of Algin 100 mlTablet/Syrup- Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses. Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses. Injection: 1 Algin 100 ml Injection 3 times daily, through Intravenous route slowly or Intramuscular route.Suppository: 20 mg Algin 100 ml suppository two or three times daily, through rectal route.Dosage of Algin 100 mlTablet/Syrup- Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses. Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses. Injection: 1 Algin 100 ml Injection 3 times daily, through Intravenous route slowly or Intramuscular route.Suppository: 20 mg Algin 100 ml suppository two or three times daily, through rectal route.Interaction of Algin 100 mlTiemonium methylsulphate tablet should not be used with other drugs without prior consult of a registered physician to avoid possible drug interaction.ContraindicationsIt should not be used in urethroprostatic disorder involving a risk of urine retension. It is contraindicated in patient with having risk of angle closure glaucoma.Side Effects of Algin 100 mlAlgin 100 ml may have the risk of hypotension & tachycardia in certain individuals.Pregnancy & LactationThe results of animal studies of Algin 100 ml did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.Precautions & WarningsCaution should be taken during treatment of patients with disorders of the prostate. Caution should also be taken in case of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal & hepatic insufficiency. The risks of visual disturbances can make it dangerous to drive or use machines.Overdose Effects of Algin 100 mlThere is not available data regarding the overdose of Tiemonium methylsulphate tablet.Storage ConditionsKeep in a dry place, away from light and heat. Keep out of the reach of children.Use In Special PopulationsPaediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.Geriatric use: Efficacy and safety were maintained with increasing age.Drug ClassesAnticholinergicsMode Of ActionAlgin 100 ml a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.PregnancyThe results of animal studies of Algin 100 ml did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.Pediatric UsesPaediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.Geriatric use: Efficacy and safety were maintained with increasing age.
Algin100 ml
Original price was: ₦4,950.00.₦4,455.00Current price is: ₦4,455.00.
14.63764
0.00004
0.00127
0.03017
3.34642
-
SaleAlgin 50 mgAlgin 50 mg is an antispasmodic drug that reduces muscles spasm of the intestine, biliary system, bladder and uterus. It is used in symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system. It is also indicated for the treatment of spasm and pain in urological and gynaecological diseases.Theropeutic ClassAnticholinergicsPharmacologyAlgin 50 mg a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.Dosage & Administration of Algin 50 mgTablet/Syrup- Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses. Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses. Injection: 1 Algin 50 mg Injection 3 times daily, through Intravenous route slowly or Intramuscular route.Suppository: 20 mg Algin 50 mg suppository two or three times daily, through rectal route.Dosage of Algin 50 mgTablet/Syrup- Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses. Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses. Injection: 1 Algin 50 mg Injection 3 times daily, through Intravenous route slowly or Intramuscular route.Suppository: 20 mg Algin 50 mg suppository two or three times daily, through rectal route.Interaction of Algin 50 mgTiemonium methylsulphate tablet should not be used with other drugs without prior consult of a registered physician to avoid possible drug interaction.ContraindicationsIt should not be used in urethroprostatic disorder involving a risk of urine retension. It is contraindicated in patient with having risk of angle closure glaucoma.Side Effects of Algin 50 mgAlgin 50 mg may have the risk of hypotension & tachycardia in certain individuals.Pregnancy & LactationThe results of animal studies of Algin 50 mg did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.Precautions & WarningsCaution should be taken during treatment of patients with disorders of the prostate. Caution should also be taken in case of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal & hepatic insufficiency. The risks of visual disturbances can make it dangerous to drive or use machines.Overdose Effects of Algin 50 mgThere is not available data regarding the overdose of Tiemonium methylsulphate tablet.Storage ConditionsKeep in a dry place, away from light and heat. Keep out of the reach of children.Use In Special PopulationsPaediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.Geriatric use: Efficacy and safety were maintained with increasing age.Drug ClassesAnticholinergicsMode Of ActionAlgin 50 mg a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.PregnancyThe results of animal studies of Algin 50 mg did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.Pediatric UsesPaediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.Geriatric use: Efficacy and safety were maintained with increasing age.
Algin50 mg
Original price was: ₦467.50.₦420.75Current price is: ₦420.75.
1.38244
0.00000
0.00012
0.00285
0.31605